Proton therapy developer Ion Beam Applications (IBA) reported an increase in total revenue for the first half of 2022, despite the fact that its backlog of sales is still impacted by the COVID-19 pandemic.
The company reported total revenues of 160 million euros ($159 million) for the first half of 2022, up 17% from the same period last year, largely due to 51.6 million euros ($51.4 million) in sales of proton therapy equipment in the U.S. and Asia.
IBA also reported a decrease of 19.5 million euros ($19.4 million) in revenue from other accelerator equipment, a 35% drop from 30.1 million euros ($30 million) reported in the first half last year, due to backlog conversion still being impacted by COVID-19 restrictions and also supply chain challenges.
In other news, the company announced the first patient has been enrolled in a clinical trial in Europe investigating the use of its proton therapy technology in patients with esophageal cancer.
